This is Huge News For Eli Lilly Investors
As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
The Australian Financial Review9d
Weight loss wars: a century on, the battle heats up
Gift 5 articles to anyone you choose each month when you subscribe. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company ...
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...